Form 4: DexCom Director Receives RSU Grant
Statement of Changes in Beneficial Ownership
DexCom Director Albert Frederick Osterloh IV was granted 1,630 restricted stock units as part of his annual compensation.
Summary
- Director Albert Frederick Osterloh IV received a grant of 1,630 restricted stock units (RSUs) on May 28, 2026.
- The RSUs represent a contingent right to receive one share of DexCom, Inc. common stock per unit upon settlement.
- The award is scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
- Following this transaction, the director holds a total of 8,691 unvested restricted stock units.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation that does not impact the company's operational or financial outlook.
Positives
- The grant aligns the director's long-term interests with those of shareholders through equity-based compensation.
Negatives
- None identified.
Risks
- The value of the equity grant is subject to market volatility and the future performance of DexCom, Inc. common stock.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that this filing is a routine disclosure of director compensation, which is standard practice for publicly traded companies to ensure transparency in executive and board-level equity holdings.
Comparison to Industry Standards
- The use of RSUs for director compensation is consistent with standard corporate governance practices in the medical device and technology sectors.
- The vesting schedule aligns with typical one-year cliff vesting structures for non-employee directors.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity grant to a board member.
Next Steps
- Vesting of the 1,630 RSUs on the earlier of May 28, 2027, or the 2027 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 2026-02-26 | Grant date of previous RSU award. |
| 2026-05-28 | Transaction date of the new RSU grant. |
| 2027-05-28 | One-year anniversary of the grant date, marking the latest possible vesting date. |
| 2029-02-26 | Final vesting date for previous RSU awards. |
Keywords
DexCom, DXCM, Form 4, Insider Trading, Director Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.